Arginine:glycine amidinotransferase deficiency

Background

AGAT deficiency was first identified in 2000, in a pair of sisters aged 4 and 6, both of whom had severe intellectual disability. The disorder is caused by deficient activity of arginine:glycine amidinotransferase, which catalyzes the first step in creatine biosynthesis—the combination of arginine and glycine to form guanidinoacetate, with ornithine as a byproduct. These reactions take place primarily in the kidney and pancreas. The clinical manifestations are caused by decreased amounts of creatine produced.

Diagnosis can be suspected from clinical findings of intellectual disability and muscle weakness. Laboratory testing of plasma and urine shows decreased levels of creatine and guanidinoacetate. Magnetic resonance spectroscopy of the brain shows an absence of creatine, a finding not specific to AGAT deficiency. Confirmation is most often done with molecular testing of GATM, identifying biallelic pathogenic variants. Uncertain findings may be confirmed by enzyme assays or by measuring creatine uptake in fibroblasts. Prenatal testing can be performed on chorionic villi samples if the causative variants in the family are known.

Treatment focuses on oral creatine supplementation to replenish cerebral creatine. Early intervention provides the best results, and treatment is most effective if started before symptoms are apparent. Treatment does not reverse intellectual disability or improve cognitive function, but all individuals showed improvement in muscle weakness. In an asymptomatic sibling started on treatment due to earlier diagnosis of an affected sibling, early intervention resulted in improved outcomes compared to untreated siblings at the same age. Treatment must be lifelong, as creatine is rapidly converted and excreted as creatinine.

The Biochemical Disruption

AGAT deficiency represents a failure at the very first chemical step of creatine production in the human body. The enzyme arginine:glycine amidinotransferase, encoded by the GATM gene, is responsible for joining the amino acids arginine and glycine together to produce guanidinoacetate, a critical intermediate in the creatine biosynthesis pathway. This reaction simultaneously generates ornithine as a byproduct and takes place predominantly within the kidney and pancreas. When GATM activity is lost or severely reduced, the entire downstream chain of creatine manufacture grinds to a halt. The consequence is a profound shortage of creatine in the tissues that depend on it most heavily—skeletal muscle and the brain. Because creatine is essential to the proper functioning of these cells, its absence manifests as the neurological and muscular deficits that define the syndrome. The rarity of the condition means that fewer than twenty affected individuals have been documented in the medical literature to date, making each case a valuable window into this otherwise obscure biochemical pathway.

Clinical Presentation and Diagnostic Pathway

The hallmark features of AGAT deficiency overlap considerably with many other neurological conditions, making diagnosis a multi-step process. Affected individuals typically present with significant intellectual disability, and some also experience seizures and noticeable muscle weakness. The condition was first brought to medical attention in the year 2000, when two sisters aged four and six were found to have severe cognitive impairment. In the laboratory, both plasma and urine analyses reveal characteristically low levels of creatine and its precursor guanidinoacetate. A particularly telling finding comes from magnetic resonance spectroscopy of the brain, which demonstrates a complete absence of the creatine signal that would normally be visible. However, this imaging result is shared across all three forms of cerebral creatine deficiency, so it cannot pinpoint AGAT deficiency on its own. Definitive confirmation requires molecular analysis of the GATM gene to identify pathogenic variants on both alleles. When genetic results are ambiguous, enzyme assays or measurements of creatine uptake in cultured fibroblasts can provide additional evidence. For families with known causative mutations, prenatal diagnosis through chorionic villus sampling is also feasible.

Genetic Architecture and Inheritance

AGAT deficiency follows a classic autosomal recessive inheritance pattern, meaning that a child must inherit a pathogenic variant of the GATM gene from each biological parent to be affected. The GATM gene resides on the long arm of chromosome 15 and encodes the enzyme that drives the initial step of creatine biosynthesis. Because both copies of the gene must carry damaging changes, carriers who possess only one affected allele typically show no symptoms at all. This recessive mechanism, combined with the extreme rarity of the disorder, explains why fewer than twenty cases have been described in the published medical literature since the syndrome was first characterized in 2000. The biallelic requirement also has practical implications for genetic counseling within families: siblings of an affected child each carry a one-in-four chance of inheriting the condition, while the remaining three-quarters will be either unaffected or carriers. The identification of specific pathogenic variants in a family opens the door to targeted prenatal and preimplantation genetic testing, offering prospective parents the option of informed reproductive decisions.

Treatment, Prognosis, and the Case for Early Intervention

The therapeutic cornerstone of AGAT deficiency is lifelong oral creatine supplementation, aimed at restoring cerebral creatine concentrations to the normal range. The timing of treatment initiation carries enormous weight: starting supplementation early in life, ideally before clinical symptoms emerge, yields the most favorable neurological outcomes. A striking illustration comes from an asymptomatic sibling who began creatine therapy after a sibling's diagnosis and showed markedly better outcomes than their untreated siblings at comparable ages. Importantly, while creatine supplementation consistently improves muscle weakness regardless of the patient's age, it does not reverse established intellectual disability or enhance cognitive function once deficits are in place. This distinction underscores why the earliest years of brain development represent the most critical window for intervention. Because the body rapidly metabolizes and excretes creatine as creatinine, supplementation must continue indefinitely to maintain therapeutic levels. Ongoing monitoring through blood and urine creatine measurements, supplemented by periodic brain spectroscopy, allows clinicians to track treatment efficacy over the patient's lifetime.